Diagnostic value of urinary monocyte chemoattractant protein-1 in evaluating the activity of lupus nephritis: a meta-analysis

Objective This study aimed to assess systematically the overall diagnostic value of urinary monocyte chemoattractant protein-1 (uMCP-1) in systemic lupus erythematosus (SLE) patients with active lupus nephritis (LN). Methods Articles from PubMed, Web of Science, EMBASE and Cochrane Library were retr...

Full description

Saved in:
Bibliographic Details
Published in:Lupus 2020-05, Vol.29 (6), p.599-606
Main Authors: Xia, Yuan-Rui, Li, Qing-Ru, Wang, Jun-Ping, Guo, Heng-Sheng, Bao, Yu-Qing, Mao, Yan-Mei, Wu, Jun, Pan, Hai-Feng, Ye, Dong-Qing
Format: Article
Language:English
Subjects:
Lupus
Lupus nephritis
Meta-analysis
Monocyte chemoattractant protein
Monocyte chemoattractant protein 1
Monocytes
Nephritis
Quality control
Statistical analysis
Systemic lupus erythematosus
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective This study aimed to assess systematically the overall diagnostic value of urinary monocyte chemoattractant protein-1 (uMCP-1) in systemic lupus erythematosus (SLE) patients with active lupus nephritis (LN). Methods Articles from PubMed, Web of Science, EMBASE and Cochrane Library were retrieved up to 5 November 2019. Study quality was evaluated using the Quality Assessment of Diagnostic Accuracy Studies-2 tool, and statistical analyses were performed. Results A total of seven original studies with 521 participants were included in this meta-analysis. The summary estimates were: sensitivity 0.89 (95% confidence interval (CI) 0.86–0.93), specificity 0.63 (95% CI 0.55–0.69), positive likelihood ratio 2.16 (95% CI 1.66–2.80), negative likelihood ratio 0.15 (95% CI 0.08–0.30), diagnostic odds ratio 19.40 (95% CI 7.24–51.96) and area under the curve 0.9042. Conclusion As a non-invasive biomarker, uMCP-1 has high diagnostic accuracy for active LN.
ISSN:0961-2033
1477-0962
DOI:10.1177/0961203320914372